Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
non-transduced cytokine-induced killer cells
- Development stage
- Unknown
- Lead developer
- University of Milano-Bicocca
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Non-transduced cytokine-induced killer (CIK) cells are a heterogeneous population of ex vivo expanded immune effector cells, primarily characterized by a CD3+CD56+ phenotype, which combines the cytotoxic potential of T lymphocytes with the MHC-unrestricted tumor recognition capabilities of natural killer (NK) cells. These cells are typically generated from peripheral blood mononuclear cells (PBMCs) through a standardized culture process involving sequential stimulation with interferon-gamma (IFN-γ), anti-CD3 monoclonal antibodies, and interleukin-2 (IL-2). Unlike CAR-CIK cells, non-transduced CIK cells have not undergone genetic modification to express chimeric antigen receptors. They exert potent antitumor activity primarily through the engagement of the NKG2D receptor with stress-induced ligands (such as MICA/B and ULBPs) expressed on malignant cells. In clinical research, they serve as a baseline cellular platform for genetic engineering or as a standalone adoptive immunotherapy due to their favorable safety profile and minimal risk of graft-versus-host disease (GvHD) in allogeneic settings. In the context of acute myeloid leukemia (AML) research, they are frequently used as a control to evaluate the enhanced specificity and efficacy of dual-CAR engineered CIK cells.
- Other names
- unmodified cytokine-induced killer cellsNT CIKnon-modified cytokine-induced killer cells
02
Targets
MICB (Major histocompatibility complex class i-related protein B)
Beyond the preview
Go deeper on non-transduced cytokine-induced killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on non-transduced cytokine-induced killer cells.